- Home
- PCYO vs ZNTL Comparison
PCYO vs ZNTL Comparison
Compare PCYO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCYO | ZNTL |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 289.0M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCYO | ZNTL |
|---|---|---|
| Price | $10.67 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 55.9K | ★ 1.6M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.50 | ★ 18.03 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.65 | $1.21 |
| 52 Week High | $12.44 | $6.95 |
Technical Indicators
Market Signals| Indicator | PCYO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 45.35 |
| Support Level | $10.64 | $3.53 |
| Resistance Level | $10.96 | $5.11 |
| Average True Range (ATR) | 0.35 | 0.44 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 67.70 | 5.30 |
Price Performance
Historical ComparisonAbout PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.